https://scholars.lib.ntu.edu.tw/handle/123456789/518359
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Hsieh, Chang-Yu | en_US |
dc.contributor.author | TSEN-FANG TSAI | en_US |
dc.creator | Hsieh, Chang-Yu;Tsen-Fang Tsai | - |
dc.date.accessioned | 2020-10-28T02:54:49Z | - |
dc.date.available | 2020-10-28T02:54:49Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 1173-2563 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/518359 | - |
dc.description.abstract | Idiosyncratic drug-induced neutropenia (DIN) is a rare, potentially fatal adverse reaction. A literature search was performed on Pubmed and Embase, targeting articles indicating neutropenia as a complication during the treatment of non-neoplastic dermatological disorders. In 66 identified articles, the common incriminated drugs included conventional oral immunomodulators, topical cytotoxic agents, antibacterials, antifungals, biologics and targeted synthetic disease-modifying antirheumatic drugs, non-steroidal anti-inflammatory drugs, and retinoids, with dapsone being reported most often. The duration of drug exposure before the diagnosis of neutropenia varied, but mostly ranged from days to weeks. The majority of patients recovered after drug discontinuation and supportive management including antibiotics and granulocyte colony-stimulating factor, but fatal cases were reported. The proposed pathogenesis of DIN consists of direct drug toxicity and immune-mediated reaction. Certain genetic variants, individual variability in enzyme efficiency, and concomitant use of other drugs may increase the risk of DIN. Being familiar with the most commonly implicated agents and risk factors helps early identification and prompt management of this potentially fatal complication. | en_US |
dc.language.iso | animation | en_US |
dc.publisher | ADIS INT LTD | en_US |
dc.relation.ispartof | Clinical drug investigation | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | azathioprine; colchicine; cytotoxic agent; dapsone; etretin; fluorouracil; granulocyte colony stimulating factor; hydroxychloroquine; isotretinoin; Janus kinase inhibitor; lenalidomide; methotrexate; minocycline; podophyllin; rituximab; salazosulfapyridine; sulfadiazine silver; terbinafine; tumor necrosis factor inhibitor; antineoplastic agent; granulocyte colony stimulating factor; bibliographic database; drug exposure; drug induced disease; genetic variability; human; neutropenia; priority journal; Review; risk factor; treatment duration; neutropenia; Antineoplastic Agents; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia | - |
dc.title | Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1007/s40261-020-00956-w | - |
dc.identifier.pmid | 32691244 | - |
dc.identifier.isi | WOS:000550635800001 | - |
dc.relation.pages | 915 | en_US |
dc.relation.journalvolume | 40 | en_US |
dc.relation.journalissue | 10 | en_US |
dc.relation.pageend | 926 | en_US |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.languageiso639-1 | animation | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Dermatology | - |
crisitem.author.dept | Dermatology-NTUH | - |
crisitem.author.orcid | 0000-0002-1498-1474 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。